JP2017502948A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017502948A5 JP2017502948A5 JP2016539110A JP2016539110A JP2017502948A5 JP 2017502948 A5 JP2017502948 A5 JP 2017502948A5 JP 2016539110 A JP2016539110 A JP 2016539110A JP 2016539110 A JP2016539110 A JP 2016539110A JP 2017502948 A5 JP2017502948 A5 JP 2017502948A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- azabicyclo
- hexane
- naphthalen
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000203 mixture Substances 0.000 claims 48
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 12
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 12
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 12
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims 12
- 150000003839 salts Chemical class 0.000 claims 11
- HKHCSWPSUSWGLI-CABCVRRESA-N (1r,5s)-1-naphthalen-2-yl-3-azabicyclo[3.1.0]hexane Chemical compound C1=CC=CC2=CC([C@@]34CNC[C@H]4C3)=CC=C21 HKHCSWPSUSWGLI-CABCVRRESA-N 0.000 claims 8
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims 8
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 claims 7
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 6
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 4
- -1 hydroxypropoxy Chemical group 0.000 claims 3
- 239000000314 lubricant Substances 0.000 claims 3
- 235000019359 magnesium stearate Nutrition 0.000 claims 3
- 239000003607 modifier Substances 0.000 claims 3
- 239000002245 particle Substances 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 claims 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims 2
- 239000011230 binding agent Substances 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 239000007884 disintegrant Substances 0.000 claims 2
- 229960001021 lactose monohydrate Drugs 0.000 claims 2
- 238000006467 substitution reaction Methods 0.000 claims 2
- 238000013268 sustained release Methods 0.000 claims 2
- 239000012730 sustained-release form Substances 0.000 claims 2
- OKMWKBLSFKFYGZ-UHFFFAOYSA-N 1-behenoylglycerol Chemical group CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 claims 1
- ZSLUVFAKFWKJRC-IGMARMGPSA-N 232Th Chemical compound [232Th] ZSLUVFAKFWKJRC-IGMARMGPSA-N 0.000 claims 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- 229930195725 Mannitol Natural products 0.000 claims 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 1
- 229920000881 Modified starch Polymers 0.000 claims 1
- 229920002472 Starch Polymers 0.000 claims 1
- 229910052776 Thorium Inorganic materials 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 229920002678 cellulose Polymers 0.000 claims 1
- 239000001913 cellulose Substances 0.000 claims 1
- 235000010980 cellulose Nutrition 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 229940049654 glyceryl behenate Drugs 0.000 claims 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims 1
- 229920003130 hypromellose 2208 Polymers 0.000 claims 1
- 229940031707 hypromellose 2208 Drugs 0.000 claims 1
- 239000000594 mannitol Substances 0.000 claims 1
- 235000010355 mannitol Nutrition 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 1
- 239000008108 microcrystalline cellulose Substances 0.000 claims 1
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 239000008107 starch Substances 0.000 claims 1
- 235000019698 starch Nutrition 0.000 claims 1
- 239000000454 talc Substances 0.000 claims 1
- 229910052623 talc Inorganic materials 0.000 claims 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361913886P | 2013-12-09 | 2013-12-09 | |
| US61/913,886 | 2013-12-09 | ||
| PCT/US2014/069416 WO2015102826A1 (en) | 2013-12-09 | 2014-12-09 | Novel compositions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017502948A JP2017502948A (ja) | 2017-01-26 |
| JP2017502948A5 true JP2017502948A5 (enExample) | 2018-01-18 |
Family
ID=53371779
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016539110A Withdrawn JP2017502948A (ja) | 2013-12-09 | 2014-12-09 | 新規な組成物 |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US9839627B2 (enExample) |
| EP (1) | EP3080080A4 (enExample) |
| JP (1) | JP2017502948A (enExample) |
| KR (1) | KR20160101012A (enExample) |
| CN (1) | CN106029637A (enExample) |
| AU (1) | AU2014374259A1 (enExample) |
| CA (1) | CA2936108A1 (enExample) |
| WO (2) | WO2015089111A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1915146A4 (en) | 2005-07-27 | 2010-06-02 | Dov Pharmaceutical Inc | NOVEL 1-ARYL-3-AZABICYCLO [3.1.0] HEXANEES. PREPARATION AND USE FOR THE TREATMENT OF NEUROPSYCHIATRIC DISEASES |
| US20140206740A1 (en) | 2011-07-30 | 2014-07-24 | Neurovance, Inc. | Use Of (1R,5S)-(+)-(Napthalen-2-yl)-3-Azabicyclo[3.1.0]Hexane In The Treatment Of Conditions Affected By Monoamine Neurotransmitters |
| CA2936108A1 (en) * | 2013-12-09 | 2015-07-09 | Neurovance, Inc. | Novel compositions |
| LT3597189T (lt) | 2015-06-17 | 2022-07-11 | Otsuka America Pharmaceutical, Inc. | Kristaliniai junginia |
| WO2018119291A1 (en) * | 2016-12-21 | 2018-06-28 | Otsuka America Pharmaceutical, Inc. | Synthetic methods |
| CN120441453A (zh) | 2018-04-26 | 2025-08-08 | 株式会社Api | 芳香族腈化合物的制造方法 |
| KR20220088777A (ko) | 2019-10-29 | 2022-06-28 | 가부시키가이샤 에이피아이 코포레이션 | 고순도 2-나프틸아세토니트릴 및 이의 제조 방법 |
| IL303767A (en) | 2021-02-23 | 2023-08-01 | Otsuka Pharma Co Ltd | Pharmaceutical formulations of centrapadin, and methods for its preparation and use |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1874298A4 (en) | 2005-03-08 | 2009-08-05 | Dov Pharmaceutical Inc | METHOD AND COMPOSITIONS FOR THE PREPARATION, FORMULATION AND USE OF 1-ARYL-3-AZABICYCLO [3,1,0] HEXANES |
| US20070082939A1 (en) | 2005-07-26 | 2007-04-12 | Lippa Arnold S | Methods and compositions for the treatment of neuropathies and related disorders |
| EP1915146A4 (en) | 2005-07-27 | 2010-06-02 | Dov Pharmaceutical Inc | NOVEL 1-ARYL-3-AZABICYCLO [3.1.0] HEXANEES. PREPARATION AND USE FOR THE TREATMENT OF NEUROPSYCHIATRIC DISEASES |
| US20090041844A1 (en) * | 2006-02-10 | 2009-02-12 | Boehringer Ingelheim International Gmbh | Modified Release Formulation |
| NZ573174A (en) * | 2006-06-01 | 2012-01-12 | Msd Consumer Care Inc | Sustained release pharmaceutical dosage form containing phenylephrine |
| US20080058535A1 (en) * | 2006-07-25 | 2008-03-06 | Zhengming Chen | Methods and compositions for production, formulation and use of 1 aryl-3-azabicyclo[3.1.0]hexanes |
| US20110034565A1 (en) * | 2008-04-18 | 2011-02-10 | University College Dublin, National University Of Ireland, Dublin | Psycho-pharmaceuticals |
| EP2646019A4 (en) | 2010-12-03 | 2014-05-21 | Euthymic Bioscience Inc | PREPARATION AND USE OF (+) - 1- (3,4-DICHLOROPHENYL) -3-AZABICYCLO- [3.1.0] HEXANE IN THE TREATMENT OF DISEASES AFFECTED BY MONOAMINE-TYPE NEUROTRANSMITTERS |
| US9085562B2 (en) * | 2011-03-03 | 2015-07-21 | Vanderbilt University | 6-alkyl-N-(pyridin-2-yl)-4-aryloxypicolinamide analogs as mGluR5 negative allosteric modulators and methods of making and using the same |
| US20140206740A1 (en) * | 2011-07-30 | 2014-07-24 | Neurovance, Inc. | Use Of (1R,5S)-(+)-(Napthalen-2-yl)-3-Azabicyclo[3.1.0]Hexane In The Treatment Of Conditions Affected By Monoamine Neurotransmitters |
| EP2819516B1 (en) * | 2011-07-30 | 2019-12-25 | Otsuka America Pharmaceutical, Inc. | Use of (1r,5s)-(+)-1-(naphthalen-2-yl)-3-azabicyclo{3.1.0}hexane in the treatment of conditions affected by monoamine neurotransmitters |
| US20140228421A1 (en) | 2011-09-07 | 2014-08-14 | Anthony McKinney | Methods For Inhibiting Native And Promiscuous Uptake Of Monoamine Neurotransmitters |
| CA2936108A1 (en) * | 2013-12-09 | 2015-07-09 | Neurovance, Inc. | Novel compositions |
| LT3597189T (lt) | 2015-06-17 | 2022-07-11 | Otsuka America Pharmaceutical, Inc. | Kristaliniai junginia |
-
2014
- 2014-12-09 CA CA2936108A patent/CA2936108A1/en not_active Abandoned
- 2014-12-09 WO PCT/US2014/069401 patent/WO2015089111A1/en not_active Ceased
- 2014-12-09 CN CN201480074992.0A patent/CN106029637A/zh active Pending
- 2014-12-09 JP JP2016539110A patent/JP2017502948A/ja not_active Withdrawn
- 2014-12-09 KR KR1020167018428A patent/KR20160101012A/ko not_active Withdrawn
- 2014-12-09 US US15/102,871 patent/US9839627B2/en active Active
- 2014-12-09 EP EP14876251.1A patent/EP3080080A4/en not_active Withdrawn
- 2014-12-09 US US15/102,949 patent/US20160303077A1/en not_active Abandoned
- 2014-12-09 AU AU2014374259A patent/AU2014374259A1/en not_active Abandoned
- 2014-12-09 WO PCT/US2014/069416 patent/WO2015102826A1/en not_active Ceased
-
2022
- 2022-03-10 US US17/691,911 patent/US20220347157A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017502948A5 (enExample) | ||
| RU2016144479A (ru) | Фармацевтические композиции для лечения заболеваний, опосредопосредованных муковисцидозным трансмембранным регулятором проводимости | |
| JP2017523206A5 (enExample) | ||
| JP2011098964A5 (enExample) | ||
| JP2014167026A5 (enExample) | ||
| JP2017511344A5 (enExample) | ||
| US20220347157A1 (en) | Sustained release pharmaceutical compositions comprising (1r, 5s)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane | |
| JP2014532638A5 (enExample) | ||
| TW201609091A (zh) | 用於口服投藥之包含依澤替米貝（ｅｚｅｔｉｍｉｂｅ）及羅舒伐他汀（ｒｏｓｕｖａｓｔａｔｉｎ）的複合調配物 | |
| FI3756650T3 (fi) | (+)-2-[1-(3-etoksi-4-metoksifenyyli)-2-metaanisulfonyylietyyli]-4-asetyyliaminoisoindoliini-1,3-dionin formulaatioita | |
| JP2017537954A5 (enExample) | ||
| JP2015533129A (ja) | チカグレロルを含む固形経口医薬製剤 | |
| AR100977A1 (es) | Formulación compuesta para la administración oral que comprende ezetimiba y rosuvastatina, y un proceso para su preparación | |
| JP2016530238A5 (enExample) | ||
| MX356105B (es) | Formulaciones de ácido ciclopropancarboxílico de {2-[(1s)-1-(3-etoxi-4-metoxi-fenil)-2-metansulfonil-etil]-3-oxo-2 ,3-dihidro-1h-isoindol-4-il}-amida. | |
| AR066924A1 (es) | Formulacion de nevirapina de liberacion prolongada | |
| US20140199382A1 (en) | Stable pharmaceutical compositions of an s1p receptor agonist | |
| JP2017502941A5 (enExample) | ||
| JP2017520619A5 (enExample) | ||
| JP2012513978A (ja) | オルメサルタン製剤処方 | |
| JP2023052398A (ja) | ４－アミノ－３－ブタン酸類縁体含有固形製剤 | |
| CA2895881C (en) | Tablet composition comprising cinacalcet hydrochloride | |
| JP2017537883A5 (enExample) | ||
| KR102548747B1 (ko) | 라록시펜, 및 비타민 d 또는 그 유도체를 포함하는 복합 캡슐제 | |
| JP2018515566A5 (enExample) |